Lundbeck has reported results from an open‑label phase 1b trial evaluating Lu AF28996, an investigational oral prodrug of a ...

Bespak has signed an MOU with SNBL to provide immediate and exclusive global access to SNBL’s proprietary nasal dry powder ...

Galderma has announced new NEMLUVIO data to be presented at Fall Clinical 2026, including a post‑hoc analysis from the ...

Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF ...

Northwest Biotherapeutics and NHS Blood and Transplant have agreed a collaboration to support production of DCVax-L, a ...

AbbVie has announced that the SMC has accepted AQUIPTA (atogepant) for acute migraine treatment in adults, only if at least two triptans were previously tried without sufficient effect, or triptans ...

Alnylam UK Limited has welcomed a Scottish Medicines Consortium decision to accept vutrisiran for adults with ATTR‑CM, enabling eligible patients to access AMVUTTRA through NHS ...

Laverock Therapeutics has announced new in vivo programmes spanning CAR‑T and genetic medicine, expanding its therapeutic ...

Mums whose babies developed life‑threatening sepsis and meningitis from group B streptococcus are urging pregnant women to ...

Atrogi has announced positive human data for ATR‑258, its first‑in‑class oral GRK2‑biased β2‑adrenergic modulator designed to improve muscle function and body composition. In an 8‑week ...

Kither Biotech has started dosing patients in its phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe ...

Teva has received US FDA approval for DEGEVMA (denosumab‑adet), a biosimilar to Xgeva, marking a further step in its Pivot to Growth strategy. The product is authorised across all Xgeva indications, ...